Arrowhead Pharmaceuticals (ARWR) reported results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome. The company said PALISADE successfully met primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides, apolipoprotein C-III, and the incidence of acute pancreatitis.
Based on these positive findings, the company plans to file a New Drug Application with the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.
Shares of Arrowhead are up 10% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.